Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $17.3500 (-1.76%) ($17.2900 - $17.8200) on Mon. Jul. 31, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.25% (three month average) | RSI | 63 | Latest Price | $17.3500(-1.76%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.2% a day on average for past five trading days. | Weekly Trend | ADMS advances 2.4% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(25%) IBB(22%) XOP(18%) ARKG(17%) IWC(17%) | Factors Impacting ADMS price | ADMS will decline at least -1.125% in a week (0% probabilities). VIXM(-11%) UUP(-11%) UNG(-9%) BNDX(-7%) TLT(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.125% (StdDev 2.25%) | Hourly BBV | 0 () | Intraday Trend | -1.8% | | | |
|
Resistance Level | $17.5 | 5 Day Moving Average | $17.76(-2.31%) | 10 Day Moving Average | $17.7(-1.98%) | 20 Day Moving Average | $17.5(-0.86%) | To recent high | -6% | To recent low | 17.7% | Market Cap | $491m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |